MEI Pharma (MEIP) Stock Forecast, Price Target & Predictions


OverviewOwnershipFinancialsChart

MEIP Stock Forecast


MEI Pharma stock forecast is as follows: a rating consensus of 'Hold', based on 3 wall street analysts offering a 1-year stock forecast.

MEIP Analyst Ratings


Hold

According to 3 Wall Street analysts, MEI Pharma's rating consensus is 'Hold'. The analyst rating breakdown for MEIP stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 3 'Hold' (100.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Jul 23, 2024LaidlawHoldDowngrade
Jul 22, 2024Brookline CapitalBuyHoldDowngrade
Feb 08, 2023JefferiesUnderperformDowngrade
Dec 06, 2022BTIGNeutralDowngrade
Apr 12, 2022Brookline CapitalBuyBuyHold

MEI Pharma's last stock rating was published by Laidlaw on Jul 23, 2024. The company Downgrade its MEIP rating from "null" to "Hold".

MEI Pharma Financial Forecast


MEI Pharma Revenue Forecast

Dec 24Sep 24Jun 24Mar 24Dec 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17Mar 08Mar 07Mar 06Mar 05Mar 04
Revenue------$5.89M$32.73M$8.73M$11.41M$9.69M$18.22M$13.39M$10.12M$2.42M$9.17M$3.83M$25.50M$1.24M$1.01M$1.16M$1.13M$1.25M$433.00K$4.50M-----
Avg Forecast--$50.00K$37.50K$100.00K$620.67K$346.75K$4.42M$4.42M$4.78M$3.44M$5.26M$10.56M$4.17M$5.41M$2.92M$3.67M$45.07M$1.58M$1.58M$1.33M$715.86K$690.71K$645.00K$9.02M$440.40K$456.00K$83.33K$93.33K$53.33K
High Forecast--$50.00K$37.75K$100.00K$620.67K$346.75K$4.42M$4.42M$4.78M$3.44M$5.26M$10.56M$4.17M$5.41M$2.92M$3.67M$45.07M$1.58M$1.58M$1.33M$715.86K$690.71K$774.00K$10.82M$528.48K$547.20K$100.00K$112.00K$64.00K
Low Forecast--$50.00K$37.25K$100.00K$620.67K$346.75K$4.42M$4.42M$4.78M$3.44M$5.26M$10.56M$4.17M$5.41M$2.92M$3.67M$45.07M$1.58M$1.58M$1.33M$715.86K$690.71K$516.00K$7.22M$352.32K$364.80K$66.67K$74.67K$42.66K
# Analysts--11111111111111010101099992016121491611
Surprise %------17.00%7.41%1.98%2.39%2.82%3.46%1.27%2.43%0.45%3.14%1.05%0.57%0.79%0.64%0.87%1.58%1.81%0.67%0.50%-----

MEI Pharma's average Quarter revenue forecast for Jun 23 based on 1 analysts is $620.67K, with a low forecast of $620.67K, and a high forecast of $620.67K. MEIP's average Quarter revenue forecast represents a -89.47% decrease compared to the company's last Quarter revenue of $5.89M (Mar 23).

MEI Pharma EBITDA Forecast

Dec 24Sep 24Jun 24Mar 24Dec 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17Mar 08Mar 07Mar 06Mar 05Mar 04
# Analysts--11111111111111010101099992016121491611
EBITDA----$-11.93M-$-16.29M$8.53M$-19.24M$-16.04M$-34.33M$-5.69M$-11.80M$-5.65M$-31.24M$-11.38M$-2.02M$-18.46M$-4.30M$-20.19M$-2.96M$3.08M$-17.33M$-5.93M$-589.00K-----
Avg Forecast--$-32.34K$-10.95M$-64.68K$-401.46K$-11.71M$-7.00M$-2.01M$-2.17M$-12.52M$-2.39M$-4.80M$-1.89M$-28.82M$-1.32M$-1.67M$-20.46M$-6.63M$-715.84K$-603.34K$-324.95K$-11.21M$-7.91M$-795.15K$-3.89M$-2.52M$-2.60M$-2.17M$-847.55K
High Forecast--$-32.34K$-8.76M$-64.68K$-401.46K$-9.37M$-5.60M$-2.01M$-2.17M$-10.02M$-2.39M$-4.80M$-1.89M$-23.06M$-1.32M$-1.67M$-20.46M$-5.31M$-715.84K$-603.34K$-324.95K$-8.97M$-6.33M$-636.12K$-3.11M$-2.01M$-2.08M$-1.74M$-678.04K
Low Forecast--$-32.34K$-13.14M$-64.68K$-401.46K$-14.05M$-8.40M$-2.01M$-2.17M$-15.03M$-2.39M$-4.80M$-1.89M$-34.59M$-1.32M$-1.67M$-20.46M$-7.96M$-715.84K$-603.34K$-324.95K$-13.46M$-9.50M$-954.18K$-4.66M$-3.02M$-3.12M$-2.61M$-1.02M
Surprise %----184.44%-1.39%-1.22%9.59%7.40%2.74%2.38%2.46%2.98%1.08%8.60%1.21%0.90%0.65%28.20%4.91%-9.48%1.55%0.75%0.74%-----

1 analysts predict MEIP's average Quarter EBITDA for Mar 23 to be $-11.71M, with a high of $-9.37M and a low of $-14.05M. This is -237.23% lower than MEI Pharma's previous annual EBITDA (Dec 22) of $8.53M.

MEI Pharma Net Income Forecast

Dec 24Sep 24Jun 24Mar 24Dec 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17Mar 08Mar 07Mar 06Mar 05Mar 04
# Analysts--11111111111111010101099992016121491611
Net Income----$-11.06M-$-14.48M$10.25M$-17.10M$-16.27M$16.97M$-5.77M$-11.88M$-5.72M$-31.31M$-11.45M$-2.09M$-18.48M$-4.33M$-20.22M$-2.99M$3.05M$-17.36M$-5.95M$-602.00K-----
Avg Forecast$-14.66M$-11.33M$-9.37M$-11.06M$-9.42M$-18.63M$-11.83M$-7.09M$-22.31M$-25.64M$-12.65M$-25.16M$-17.51M$-22.45M$-28.89M$-17.54M$-10.92M$28.64M$-6.68M$-21.84M$-21.98M$-25.88M$-11.23M$-7.93M$-812.70K$-3.89M$-2.52M$-2.60M$-2.17M$-847.55K
High Forecast$-14.66M$-11.33M$-9.37M$-8.85M$-8.58M$-18.63M$-9.46M$-5.67M$-22.31M$-25.64M$-10.12M$-25.16M$-17.51M$-22.45M$-23.11M$-17.54M$-10.92M$28.64M$-5.34M$-21.84M$-21.98M$-25.88M$-8.98M$-6.34M$-650.16K$-3.11M$-2.02M$-2.08M$-1.74M$-678.04K
Low Forecast$-14.66M$-11.33M$-9.37M$-13.27M$-10.26M$-18.63M$-14.19M$-8.51M$-22.31M$-25.64M$-15.18M$-25.16M$-17.51M$-22.45M$-34.67M$-17.54M$-10.92M$28.64M$-8.01M$-21.84M$-21.98M$-25.88M$-13.48M$-9.52M$-975.24K$-4.66M$-3.02M$-3.12M$-2.61M$-1.02M
Surprise %----1.17%-1.22%-1.45%0.77%0.63%-1.34%0.23%0.68%0.25%1.08%0.65%0.19%-0.65%0.65%0.93%0.14%-0.12%1.55%0.75%0.74%-----

MEI Pharma's average Quarter net income forecast for Mar 23 is $-11.83M, with a range of $-14.19M to $-9.46M. MEIP's average Quarter net income forecast represents a -215.37% decrease compared to the company's last Quarter net income of $10.25M (Dec 22).

MEI Pharma SG&A Forecast

Dec 24Sep 24Jun 24Mar 24Dec 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17Mar 08Mar 07Mar 06Mar 05Mar 04
# Analysts--11111111111111010101099992016121491611
SG&A----$8.02M-$7.18M$8.50M$7.49M$5.77M$8.93M$7.93M$7.91M$6.63M$6.21M$5.65M$5.92M$4.53M$3.86M$4.20M$4.13M$3.74M$3.63M$2.49M$2.15M-----
Avg Forecast--$33.20K$24.90K$66.40K$412.14K$230.25K$2.93M$2.93M$3.17M$2.28M$3.49M$7.01M$2.77M$3.59M$1.94M$2.44M$29.93M$1.05M$1.05M$882.60K$475.35K$458.65K$428.30K$2.91M$292.44K$302.80K$55.34K$61.98K$35.41K
High Forecast--$33.20K$25.07K$66.40K$412.14K$230.25K$2.93M$2.93M$3.17M$2.28M$3.49M$7.01M$2.77M$3.59M$1.94M$2.44M$29.93M$1.05M$1.05M$882.60K$475.35K$458.65K$513.96K$3.49M$350.92K$363.36K$66.40K$74.37K$42.50K
Low Forecast--$33.20K$24.73K$66.40K$412.14K$230.25K$2.93M$2.93M$3.17M$2.28M$3.49M$7.01M$2.77M$3.59M$1.94M$2.44M$29.93M$1.05M$1.05M$882.60K$475.35K$458.65K$342.64K$2.32M$233.95K$242.24K$44.27K$49.58K$28.33K
Surprise %----120.75%-31.19%2.90%2.55%1.82%3.91%2.27%1.13%2.40%1.73%2.92%2.43%0.15%3.69%4.01%4.68%7.88%7.92%5.80%0.74%-----

MEI Pharma's average Quarter SG&A projection for Mar 24 is $24.90K, based on 1 Wall Street analysts, with a range of $24.73K to $25.07K. The forecast indicates a -99.69% fall compared to MEIP last annual SG&A of $8.02M (Dec 23).

MEI Pharma EPS Forecast

Dec 24Sep 24Jun 24Mar 24Dec 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17Mar 08Mar 07Mar 06Mar 05Mar 04
# Analysts--11111111111111010101099992016121491611
EPS----$-1.66-$-2.17$0.08$-0.13$-0.13$0.13$-0.05$-0.11$-0.05$-0.28$-0.10$-0.02$-0.16$-0.04$-0.26$-0.04$0.04$-0.24$-0.16$-0.02-----
Avg Forecast$-2.20$-1.70$-1.41$-1.49$-1.41$-2.80$-2.90$-3.03$-3.35$-3.85$-3.67$-3.78$-2.63$-3.37$-3.12$-2.63$-1.64$4.30$-2.60$-3.28$-3.30$-3.89$-3.37$-0.32$-0.05$-4.20$-7.02$-2.40$-3.00$-0.66
High Forecast$-2.20$-1.70$-1.41$-1.49$-1.29$-2.80$-2.90$-3.03$-3.35$-3.85$-3.67$-3.78$-2.63$-3.37$-3.12$-2.63$-1.64$4.30$-2.60$-3.28$-3.30$-3.89$-3.37$-0.26$-0.04$-3.36$-5.62$-1.92$-2.40$-0.53
Low Forecast$-2.20$-1.70$-1.41$-1.49$-1.54$-2.80$-2.90$-3.03$-3.35$-3.85$-3.67$-3.78$-2.63$-3.37$-3.12$-2.63$-1.64$4.30$-2.60$-3.28$-3.30$-3.89$-3.37$-0.38$-0.06$-5.04$-8.42$-2.88$-3.60$-0.79
Surprise %----1.17%-0.75%-0.03%0.04%0.03%-0.04%0.01%0.04%0.02%0.09%0.04%0.01%-0.04%0.02%0.08%0.01%-0.01%0.07%0.50%0.40%-----

According to 1 Wall Street analysts, MEI Pharma's projected average Quarter EPS for Mar 23 is $-2.90, with a low estimate of $-2.90 and a high estimate of $-2.90. This represents a -3725.00% decrease compared to MEIP previous annual EPS of $0.08 (Dec 22).

MEI Pharma Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
VINCVincerx Pharma$0.19$2.00952.63%Buy
SPROSpero Therapeutics$1.04$10.00861.54%Buy
ATXIAvenue Therapeutics$1.66$12.00622.89%Buy
TILInstil Bio$21.69$150.00591.56%Hold
MEIPMEI Pharma$2.60$15.00476.92%Buy
INZYInozyme Pharma$2.94$16.00444.22%Buy
ZURAZura Bio$2.51$10.00298.41%Buy
ABOSAcumen Pharmaceuticals$1.96$7.00257.14%Buy
CTMXCytomX Therapeutics$1.13$3.47207.08%Buy
TERNTerns Pharmaceuticals$6.80$18.67174.56%Buy
KZRKezar Life Sciences$6.52$17.50168.40%Buy
ASMBAssembly Biosciences$14.28$35.50148.60%Buy
ACHLAchilles Therapeutics$0.97$2.00106.19%Buy
DAWNDay One Biopharmaceuticals$12.64$24.0089.87%Buy
OCULOcular Therapeutix$9.02$16.0077.38%Buy
HOOKHOOKIPA Pharma$2.13$3.0040.85%Buy

MEIP Forecast FAQ


Is MEI Pharma a good buy?

No, according to 3 Wall Street analysts, MEI Pharma (MEIP) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of MEIP's total ratings.

What are MEI Pharma's analysts' financial forecasts?

MEI Pharma's analysts financial forecasts for the fiscal year (Jun 2023) are as follows: average revenue is $9.8M (high $9.8M, low $9.8M), average EBITDA is $-21.117M (high $-17.375M, low $-24.859M), average net income is $-59.868M (high $-56.083M, low $-63.652M), average SG&A $6.51M (high $6.51M, low $6.51M), and average EPS is $-12.08 (high $-12.08, low $-12.08). MEIP's analysts financial forecasts for the fiscal year (Jun 2024) are as follows: average revenue is $187.5K (high $187.75K, low $187.25K), average EBITDA is $-11.044M (high $-8.855M, low $-13.234M), average net income is $-29.85M (high $-26.799M, low $-32.9M), average SG&A $124.5K (high $124.67K, low $124.34K), and average EPS is $-4.307 (high $-4.181, low $-4.433).

Did the MEIP's actual financial results beat the analysts' financial forecasts?

Based on MEI Pharma's last annual report (Jun 2022), the company's revenue was $40.7M, beating the average analysts forecast of $24.04M by 69.28%. Apple's EBITDA was $-95.91M, beating the average prediction of $-21.874M by 338.46%. The company's net income was $-54.738M, missing the average estimation of $-80.962M by -32.39%. Apple's SG&A was $30.54M, beating the average forecast of $15.96M by 91.31%. Lastly, the company's EPS was $-0.44, missing the average prediction of $-13.928 by -96.84%. In terms of the last quarterly report (Mar 2023), MEI Pharma's revenue was $5.89M, beating the average analysts' forecast of $346.75K by 1599.78%. The company's EBITDA was $-16.294M, beating the average prediction of $-11.708M by 39.17%. MEI Pharma's net income was $-14.485M, beating the average estimation of $-11.829M by 22.45%. The company's SG&A was $7.18M, beating the average forecast of $230.25K by 3018.77%. Lastly, the company's EPS was $-2.17, missing the average prediction of $-2.9 by -25.17%